Figure 5.

Combination of SHR2554 and HBI8000 exhibited synergistic anti-tumor effect in DLBCL models in vivo. Four DLBCL-derived xenograft models (CDXs: SU-DHL-6 and U2932; PDXs: PDX001-EZH2 WT and PDX002-EZH2 Y641N) were used to assess the anti-tumor activity of drug combination in vivo. (a) Tumor size curves derived from four models. (b) Tumor weight derived from four models. (c) Representative immunohistochemistry staining of Ki67 is shown (Scale bar 200 μM). (d) Tumor tissues from four models were used to evaluate cell cycle, apoptosis and histone modification-related pathway by Western blot. Detailed information about Western Blot can be found at supplementary materials. ** p < 0.01, *** p < 0.001, # p < 0.05, ## p < 0.01, ### p < 0.001, compared with vehicle group.